Open AccessS200: IMPROVED OVERALL SURVIVAL WITH FIRST‐LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6‐YEAR ANALYSIS OF ECHELON‐1
Author(s) -
Hutchings M.,
Ansell S. M.,
Straus D. J.,
Connors J. M.,
Kim W. S.,
Gallamini A.,
Ramchandren R.,
Friedberg J. W.,
Advani R.,
Evens A. M.,
Smolewski P.,
Savage K. J.,
Bartlett N. L.,
Eom H.S.,
Abramson J. S.,
Dong C.,
Campana F.,
Fenton K.,
Puhlmann M.,
Radford J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843692.94815.d7
Subject(s) - abvd , brentuximab vedotin , dacarbazine , medicine , vinblastine , oncology , interim analysis , population , progression free survival , chemotherapy regimen , bleomycin , lymphoma , surgery , chemotherapy , vincristine , randomized controlled trial , hodgkin lymphoma , cyclophosphamide , environmental health